Bayer Kogenate FS Supply To Reach 80% Of 2000 Factor VIII Levels By 2002
Executive Summary
Bayer expects Kogenate FS recombinant factor VIII supply in 2002 to be approximately 80% of levels in 2000, and to exceed previous quantities by 2003, Bayer board member Frank Morich, MD, told analysts.
You may also be interested in...
Bayer May Cut U.S. Sales Force After Cipro Generics Enter Market
Bayer is looking to make further cuts in its U.S. pharmaceutical division following entry of Cipro generics, Bayer Health Care Chairman Arthur Higgins said during an earnings conference Aug. 3
Bayer May Cut U.S. Sales Force After Cipro Generics Enter Market
Bayer is looking to make further cuts in its U.S. pharmaceutical division following entry of Cipro generics, Bayer Health Care Chairman Arthur Higgins said during an earnings conference Aug. 3
Wyeth To File Refacto AF Second Quarter; Will Launch End Supply Problems?
Wyeth plans to file its second-generation antihemophilic factor VIII product Refacto AF during the second quarter, Wyeth President-Global Pharmaceuticals Bernard Poussot said during a Jan. 28 analyst call